Single-dose treatment for paucibacillary leprosy; field implications.
Revankar
C R
CR
Pai
V V
VV
Samy
M S
MS
Ganapati
R
R
D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000627:therapeutic use; D015331:Cohort Studies; D016001:Confidence Intervals; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D006801:Humans; D007917:Leprostatic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D007918:Leprosy / Q000188:drug therapy*; D008911:Minocycline / Q000008:administration & dosage / Q000627:therapeutic use; D009166:Mycobacterium leprae / Q000187:drug effects*; D015242:Ofloxacin / Q000008:administration & dosage / Q000627:therapeutic use; D012293:Rifampin / Q000008:administration & dosage / Q000627:therapeutic use; D055502:Secondary Prevention
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D007917:Leprostatic Agents; D015242:Ofloxacin; D008911:Minocycline; D012293:Rifampin